Latest Conference Articles

March 26th 2018, 8:52pm

SGO Annual Meeting

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.

March 26th 2018, 8:52pm

SGO Annual Meeting

To access the value of the maintenance therapies and biomarkers to direct treatment for patients with platinum-sensitive recurrent ovarian cancer, investigators used ASCO’s Net Health Benefit and ESMO’s Magnitude of Clinical Benefit Scale.

March 26th 2018, 3:29am

SGO Annual Meeting

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.

March 25th 2018, 10:28pm

SGO Annual Meeting

Baseline body weight and platelet counts were early predictors for future AE-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

March 25th 2018, 9:08pm

SGO Annual Meeting

Implementation of an "ultra-restrictive" opioid prescription protocol for gynecologic surgery led to an 89% reduction in the number of opioid tablets dispensed at discharge and a high rate of patient satisfaction.

March 25th 2018, 8:41pm

SGO Annual Meeting

Bradley J. Monk, MD, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses how to decide which PARP inhibitor to use when treating a patient with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

March 25th 2018, 8:23pm

SGO Annual Meeting

The use of immune checkpoint inhibitors in women with recurrent ovarian cancer has a clinical benefit but a higher rate of adverse events than previously reported in other tumor types.

March 13th 2018, 1:47am

PER® Winter Lung Cancer Conference

Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.

March 13th 2018, 1:16am

PER® Winter Lung Cancer Conference

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the important of addressing financial toxicity during the 5th Annual Miami Lung Cancer Conference.

March 13th 2018, 12:47am

PER® Winter Lung Cancer Conference

ROS1, NTRK, MET, and HER2 are all less common molecular targets found in non–small cell lung cancer, but emerging therapeutic strategies are being explored to attack these abnormalities.

March 12th 2018, 11:47pm

PER® Winter Lung Cancer Conference

Heather Wakelee, MD, professor of medicine, division of oncology, Stanford University, discusses first-line therapy for patients with EGFR-mutant lung cancer.

March 12th 2018, 9:11pm

PER® Winter Lung Cancer Conference

Upfront testing for BRAF V600E mutations is necessary for patients with non–small cell lung cancer, but if results are positive, physicians are unsure when to administer BRAF/MEK combination therapy—and they must be prepared to manage the associated adverse events.

March 12th 2018, 1:11am

PER® Miami Breast Cancer Conference

Abemaciclib (Verzenio) has quickly amassed several clinical indications for patients with metastatic breast cancer, and is the only CDK4/6 inhibitor approved as a single agent.

March 11th 2018, 8:27pm

PER® Miami Breast Cancer Conference

Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, and chair of the Miami Breast Cancer Conference, discusses the evolution of breast cancer treatment in recent years. Borgen shared his insight in an interview during the meeting.

March 11th 2018, 5:25am

PER® Winter Lung Cancer Conference

Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.

March 11th 2018, 3:41am

PER® Winter Lung Cancer Conference

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

March 11th 2018, 3:05am

PER® Miami Breast Cancer Conference

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses novel agents that are emerging in the HER2-positive breast cancer space. Hurvitz shared this insight in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.

March 11th 2018, 2:57am

PER® Winter Lung Cancer Conference

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in the first-line treatment of non–small cell lung cancer during the 5th Annual Miami Lung Cancer Conference.

March 11th 2018, 2:49am

PER® Winter Lung Cancer Conference

Immune-based therapies continue to show promising signals for patients with small cell lung cancer and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit.

March 11th 2018, 2:40am

PER® Miami Breast Cancer Conference

Endocrine therapy can achieve tumor reduction for patients with ER-positive breast cancer, possibly avoiding the need for chemotherapy or even surgery in some patients; however, deciding how long to continue this therapy can be tricky.